Merck Reports P-III Trial (NRGGY018) Results of -Keytruda (pembrolizumab) as 1L Treatment for Advanced or Recurrent Endometrial Carcinoma
- The P-III trial evaluating Keytruda + CT vs CT alone in 816 patients with stage III-IV or recurrent EC whose cancer was either pMMR or dMMR
- The results showed an improvement in PFS regardless of mismatch repair status. In the pMMR & dMMR cohort of 591 & 225 evaluable patients, 46% & 70% reduction in risk of disease progression or death after a median follow-up of 7.9 & 12mos., m-PFS (13.1 vs 8.7mos. & not reached vs 7.6mos.), respectively
- The safety profile was consistent with prior reported studies with no new safety signals. In both cohorts, grade 3-5 AEs (55.1% vs 45.3% & 63.3% vs 47.2%) & no Keytruda-related AEs led to death. The results are being presented at SGO 2023; published in the NEJM & discussed with regulatory authorities globally
Ref: keytruda | Image: keytruda
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.